Navigation Links
Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
Date:5/4/2009

genic factors such as vascular endothelial growth factors (VEGF).

About Potentia

Potentia Pharmaceuticals, Inc. is a biotechnology company focused on developing novel therapeutics to address chronic inflammatory diseases, with an initial emphasis on diseases of the eye such as age-related macular degeneration.


'/>"/>
SOURCE Potentia Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
2. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
3. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
4. Study Shows Leconotide, an Investigative Calcium Channel Blocker, Has Potential as a Selective, Efficacious, Non-Opioid Pain Treatment
5. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
6. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
7. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
8. Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
9. Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkins Lymphoma
10. Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
11. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 Today, a group of national medical ... H.R. 3590, the Patient Protection and Affordable Care Act, ... its way towards a final vote in the coming ... Senators to vote against a health care bill that ... first hand that our health care system needs reform ...
(Date:12/16/2009)... to Millennium Research Group (MRG), the global authority ... minimally invasive spinal fusion market will expand at ... through 2014, reimbursement concerns in certain segments will ... had been forecast at almost 20%. ,, MRG,s ... 2010 report finds that the ...
(Date:12/16/2009)... -- HDT Engineered Technologies (HDT), a leader in ... principal subcontractor for the mechanical development of the ... anthropromorphic arm technology that will give patients improved, ... including a sense of touch. ,, As ... (DARPA) Revolutionizing Prosthetics 2009 (RP2009) project, the MPL ...
Breaking Medicine Technology:Physician Groups Oppose Current Senate Health Care Reform Bill 2Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 2Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 3HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program 2Smog Tougher on the Obese 59542 1Smog Tougher on the Obese 59542 2Smog Tougher on the Obese 59542 3ResearchToolkit org provides one stop Web resource for health researchers 59539 1ResearchToolkit org provides one stop Web resource for health researchers 59539 2ResearchToolkit org provides one stop Web resource for health researchers 59539 3Smoking bans reduce the risk of heart attacks associated with secondhand smoke 59536 1Smoking bans reduce the risk of heart attacks associated with secondhand smoke 59536 2
... ROCHESTER, N.Y., May 02, 2007 /PRNewswire/ -- A new ... winter may have been,less effective than the vaccines used ... before last winter were only 24 percent,less likely to ... The,differences were larger in two previous Harris Polls on ...
... the range of migraine symptoms, BOSTON, May 02, ... symptoms such as nausea or,sensitivity to light and ... pain or sinus pain that are not traditionally,associated ... patients using the investigational migraine,treatment Trexima early in ...
Other Medicine Technology:Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 2Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 3Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 4Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 5Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 6Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 2Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 3Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 4Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 5
(Date:12/17/2009)... fill/finish of nimotuzumab , ... ... of Therapure Biopharma Inc. and David Allan, Chairman and CEO ... agreement under which Therapure Biopharma will provide aseptic fill and ... YM’s majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre ...
(Date:12/17/2009)... (NYSE: CFN ) announced today that it ... TRC Capital Corporation (TRC) to purchase up to four ... percent of the shares of common stock outstanding. TRC,s ... below the share closing price of CareFusion common stock ... prior to the offer. CareFusion also noted that the ...
(Date:12/17/2009)... December 17 Researchers from the School ... University in the UK are today,encouraging families ... the,New Year following concerning research* that shows two-thirds ... as a family (68%), with the,Portuguese being the ... to,walk together. , According ...
(Date:12/17/2009)... levels trended in 2009 and over the past three years and ... ... (Vocus) December 17, 2009 -- Morehead, the human capital research firm, ... Year in Review.” The free hour-long webinar will be broadcast ... , ,Join Rod Wilkes, M.S., Morehead’s SVP, Consulting Services and Trevor ...
(Date:12/17/2009)... Cost/Risk Analysis reports, activity measures and outcomes reporting to monitor ... reduced claim costs and positive return on investment over the ... ... Jacksonville, FL (PRWEB) December 17, 2009 -- HealthScreen ... clinical/claims based cost risk analysis along with personalized nurse care, ...
Breaking Medicine News(10 mins):Health News:Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 2Health News:Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 3Health News:Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 4Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2Health News:The Family Walk - a Dying Tradition Around the World? 2Health News:Morehead Presents Webinar on "The State of Employee Engagement: A Year in Review" 2Health News:Baptist Health System Selects HealthScreen Disease Management for Employee Health Management Services 2
... Rapid improvement in verbal abilities, word finding, and aphasia in Alzheimer,s ... immune treatment is reported. These findings may be related to immune ... research. , ... Los Angeles, CA (PRWEB) August 5, ...
... Award-Winning Actress, Singer and Author to Serve as Emcee at ... September 7 Beverly Hilton ... will join together at the Los Angeles Jewish Home,s 8th Annual,Celebration ... Hotel. The event will honor Jacqui Fogel, Dorothy Goren, and Reggie,Scheer ...
... Children who are given antibiotics in their first three months often ... probably more due to the presence of chest infections than to ... research carried out by researchers in New Zealand, and published in ... This work built on the fact that the prevalence both of ...
... InNexus,Biotechnology Inc., (TSX VENTURE: IXS.V; OTC Bulletin Board: ... the,next generation of monoclonal antibodies based on its ... of a new product,designated DXLr120 (CD20). This is ... and was developed using new recombinant methods to ...
... a Million Patients Using New Drug Safety Monitoring Service; ... 30,000 More Register ... half a,million Americans now have the safety of their medications automatically,monitored ... new patients registering weekly., Founded by drug safety researchers in ...
... Care,Innovations, LLC, a subsidiary of Wound Management Technologies, ... has entered into a,confidentiality agreement with a company ... products, CellerateRx(R), in Taiwan. "We have,had a tremendous ... states Cathy Bradshaw, President of Wound Care,Innovations. "We ...
Other Medicine News:Health News:New Drug May Help Combat Alzheimer's 2Health News:New Drug May Help Combat Alzheimer's 3Health News:Three Noted 'Women of Valor' to be Honored at Los Angeles Jewish Home Gala Dinner 2Health News:Three Noted 'Women of Valor' to be Honored at Los Angeles Jewish Home Gala Dinner 3Health News:Wheezing after early-life antibiotics 2Health News:InNexus Biotechnology Announces Third Antibody and Expands Pipeline of Anticancer Compounds 2Health News:InNexus Biotechnology Announces Third Antibody and Expands Pipeline of Anticancer Compounds 3Health News:iGuard.org Reaches 500,000-Member Milestone 12 Months Early 2Health News:Wound Management Technologies, Inc. Announces Products to Be Registered in Taiwan 2
... Wrist OTS is an off-the-shelf wrist orthotic designed to ... 3 pre-set ranges-of-motion (20°,35° and 50°). , ,Indications: ... with TFCC tear-triangular fibrocartilage complex , Coles ... , Partial tendon rupture , ...
The Universal Wrist/Forearm Splint is ideal for post-surgical immobilization, post-fracture casting, wrist sprains and strains....
The Contoured Wrist/Forearm Support provides comfort for post-surgical immobilization, post-fracture casting, and wrist sprains and strains....
ManuTrain is an active wrist support that has optional features for increased stabilization....
Medicine Products: